AXGN vs. ARQT

Last updated Jun 4, 2026

AXGN (AxoGen, Inc.) and ARQT (Arcutis Biotherapeutics, Inc.) are both stocks. Both are in the Healthcare sector — AXGN in Medical Devices, ARQT in Biotechnology. Over the past 5 years, AXGN returned 16.44%/yr vs -4.14%/yr for ARQT. At a 0.30 correlation, their price movements are largely independent.

Performance

AXGN vs. ARQT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in AxoGen, Inc. (AXGN) and Arcutis Biotherapeutics, Inc. (ARQT). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, AXGN achieves a 24.14% return, which is significantly higher than ARQT's -26.48% return.

AXGN

• 1D: 2.97%
• 1M: -4.69%
• YTD: 24.14%
• 6M: 43.42%
• 1Y: 257.66%
• 3Y*: 66.26%
• 5Y*: 16.44%
• 10Y*: 21.66%

ARQT

• 1D: 2.69%
• 1M: -9.11%
• YTD: -26.48%
• 6M: -28.74%
• 1Y: 60.89%
• 3Y*: 37.57%
• 5Y*: -4.14%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

AXGN vs. ARQT - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
AXGN AxoGen, Inc.	24.14%	98.60%	141.29%	-31.56%	6.51%	-47.65%	44.82%
ARQT Arcutis Biotherapeutics, Inc.	-26.48%	108.47%	331.27%	-78.18%	-28.64%	-26.27%	29.04%

Correlation

The correlation between AXGN and ARQT is 0.27, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.27
Correlation (3Y) Calculated over the trailing 3-year period	0.30
Correlation (5Y) Calculated over the trailing 5-year period	0.33
Correlation (All Time) Calculated using the full available price history since Feb 3, 2020	0.30

Fundamentals

Market Cap AXGN : $2.10B ARQT : $2.76B
EPS AXGN : -$0.66 ARQT : -$0.02
PS Ratio AXGN : 8.11 ARQT : 6.74
PB Ratio AXGN : 8.56 ARQT : 14.56
Total Revenue (TTM) AXGN : $238.11M ARQT : $415.62M
Gross Profit (TTM) AXGN : $178.61M ARQT : $377.98M
EBITDA (TTM) AXGN : $5.69M ARQT : $12.21M

Return for Risk

AXGN vs. ARQT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AXGN

AXGN Risk / Return Rank: 98
AXGN Sharpe Ratio Rank: 98
AXGN Sortino Ratio Rank: 97
AXGN Omega Ratio Rank: 95
AXGN Calmar Ratio Rank: 98
AXGN Martin Ratio Rank: 99

ARQT

ARQT Risk / Return Rank: 71
ARQT Sharpe Ratio Rank: 73
ARQT Sortino Ratio Rank: 72
ARQT Omega Ratio Rank: 70
ARQT Calmar Ratio Rank: 70
ARQT Martin Ratio Rank: 71

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AXGN vs. ARQT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for AxoGen, Inc. (AXGN) and Arcutis Biotherapeutics, Inc. (ARQT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	AXGN	ARQT	Difference
Sharpe ratio Return per unit of total volatility	4.78	1.06	+3.72
Sortino ratio Return per unit of downside risk	4.92	1.86	+3.06
Omega ratio Gain probability vs. loss probability	1.60	1.23	+0.37
Calmar ratio Return relative to maximum drawdown	13.44	1.63	+11.81
Martin ratio Return relative to average drawdown	43.94	3.90	+40.04
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

AXGN vs. ARQT - Sharpe Ratio Comparison

The current AXGN Sharpe Ratio is 4.78, which is higher than the ARQT Sharpe Ratio of 1.06. The chart below compares the historical Sharpe Ratios of AXGN and ARQT, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	AXGN	ARQT	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	4.78	1.06	+3.72
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.26	-0.06	+0.32
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.35	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.05	-0.00	+0.06

Drawdowns

AXGN vs. ARQT - Drawdown Comparison

The maximum AXGN drawdown since its inception was -98.49%, roughly equal to the maximum ARQT drawdown of -95.02%. Use the drawdown chart below to compare losses from any high point for AXGN and ARQT.

Drawdown Indicators

	AXGN	ARQT	Difference
Max Drawdown Largest peak-to-trough decline	-98.49%	-95.02%	-3.47%
Max Drawdown (1Y) Largest decline over 1 year	-19.30%	-37.50%	+18.20%
Max Drawdown (3Y) Largest decline over 3 years	-62.36%	-83.24%	+20.88%
Max Drawdown (5Y) Largest decline over 5 years	-83.69%	-93.67%	+9.98%
Max Drawdown (10Y) Largest decline over 10 years	-93.54%	—	—
Current Drawdown Current decline from peak	-27.32%	-42.27%	+14.95%
Average Drawdown Average peak-to-trough decline	-64.90%	-50.15%	-14.75%
Ulcer Index Depth and duration of drawdowns from previous peaks	6.25%	15.65%	-9.40%

Volatility

AXGN vs. ARQT - Volatility Comparison

The current volatility for AxoGen, Inc. (AXGN) is 9.77%, while Arcutis Biotherapeutics, Inc. (ARQT) has a volatility of 20.15%. This indicates that AXGN experiences smaller price fluctuations and is considered to be less risky than ARQT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	AXGN	ARQT	Difference
Volatility (1M) Calculated over the trailing 1-month period	9.77%	20.15%	-10.38%
Volatility (6M) Calculated over the trailing 6-month period	37.39%	36.79%	+0.60%
Volatility (1Y) Calculated over the trailing 1-year period	54.34%	57.58%	-3.24%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	64.09%	71.79%	-7.70%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	62.05%	76.98%	-14.93%

Dividends

AXGN vs. ARQT - Dividend Comparison

Neither AXGN nor ARQT has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

AXGN vs. ARQT - Profitability Comparison

The chart below illustrates the profitability comparison between AxoGen, Inc. and Arcutis Biotherapeutics, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

AXGN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, AxoGen, Inc. reported a gross profit of 46.19M and revenue of 61.46M. Therefore, the gross margin over that period was 75.2%.

ARQT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Arcutis Biotherapeutics, Inc. reported a gross profit of 95.61M and revenue of 105.40M. Therefore, the gross margin over that period was 90.7%.

AXGN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, AxoGen, Inc. reported an operating income of -2.83M and revenue of 61.46M, resulting in an operating margin of -4.6%.

ARQT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Arcutis Biotherapeutics, Inc. reported an operating income of -9.09M and revenue of 105.40M, resulting in an operating margin of -8.6%.

AXGN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, AxoGen, Inc. reported a net income of -19.58M and revenue of 61.46M, resulting in a net margin of -31.9%.

ARQT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Arcutis Biotherapeutics, Inc. reported a net income of -11.30M and revenue of 105.40M, resulting in a net margin of -10.7%.

Frequently Asked Questions

Can I hold both AXGN and ARQT in my portfolio?

AXGN and ARQT have a correlation of 0.27, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, AXGN or ARQT?

ARQT has higher volatility (20.15%) compared to AXGN (9.77%). In terms of maximum drawdown, AXGN dropped -98.49% vs ARQT's -95.02%.

Which has better risk-adjusted returns?

AXGN currently has the higher Sharpe Ratio (4.78 vs 1.06), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.